# A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382

> **NCT01482611** · PHASE1 · COMPLETED · sponsor: **Janssen R&D Ireland** · enrollment: 35 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** JNJ-47910382
- **DRUG:** JNJ-47910382
- **DRUG:** JNJ-47910382
- **DRUG:** JNJ-47910382
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01482611
- **Lead sponsor:** Janssen R&D Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2013-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01482611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01482611, "A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT01482611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*